Form 4: Gossamer Bio CEO Awarded Significant Equity Package

Gossamer Bio's President and CEO, Faheem Hasnain, received a substantial restricted stock unit award and stock options, signaling long-term incentive alignment.

Summary

• Faheem Hasnain, President & CEO and Director of Gossamer Bio, Inc. (GOSS), reported transactions on January 2, 2026.
• Acquired 280,000 shares of Common Stock as a restricted stock unit (RSU) award at a price of $0.
• These RSUs will vest in four equal annual installments, contingent on continuous service to the Issuer on each vesting date.
• Acquired 1,680,000 stock options with an exercise price of $2.88.
• The stock options will vest 25% on January 2, 2027, and then 1/48th of the total number of shares subject to the option will vest on the last day of each one-month period thereafter, also contingent on continuous service, and expire on January 1, 2036.
• Following these transactions, Hasnain directly owns 837,793 shares of Common Stock and 1,680,000 stock options.
• An additional 5,408,073 shares of Common Stock are indirectly owned by a family trust.

Sentiment

Score: 7

Explanation: The filing reports significant equity awards to the CEO, which generally aligns management's long-term interests with shareholders. This is a positive signal for governance and executive commitment, though it is a compensation report rather than a direct performance update.

Positives

• Significant equity awards, including 280,000 restricted stock units and 1,680,000 stock options, align the President & CEO's long-term interests with those of shareholders.
• The multi-year vesting schedules for both the RSUs and stock options incentivize continuous service and sustained performance, fostering long-term commitment from executive leadership.

Negatives

• The issuance of new equity awards, particularly stock options, introduces potential future dilution for existing shareholders upon their exercise and the vesting of restricted stock units, although this is a standard component of executive compensation.

Risks

• The value of the equity awards is directly tied to the future performance of Gossamer Bio's stock, meaning the awards could decrease in value if the stock price declines.
• Vesting of both the restricted stock units and stock options is subject to the reporting person's continuous service to the Issuer, meaning the awards could be forfeited if employment terminates before vesting.

Future Outlook

The substantial equity awards for the President & CEO suggest a long-term commitment to the company's success and future growth, as the value of these awards is directly tied to the company's stock performance over the coming years. This aligns executive incentives with the goal of creating shareholder value over the long term.

Industry Context

Granting equity awards such as restricted stock units and stock options is a common and standard practice in the biotechnology and pharmaceutical industries. These awards are crucial tools for attracting, retaining, and incentivizing key executives by aligning their compensation with shareholder interests and encouraging long-term value creation, consistent with broader industry compensation trends.

Comparison to Industry Standards

• The structure of these equity awards, including a mix of restricted stock units and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices observed across the U.S. biotech sector.
• While the specific size of the awards varies based on factors like company stage, market capitalization, and individual executive performance, the use of such equity instruments is a globally recognized benchmark for incentivizing long-term value creation in growth-oriented industries.

Stakeholder Impact

• Shareholders: The awards align management's interests with shareholders, potentially leading to better long-term performance. However, they also represent potential future dilution upon vesting and exercise of the equity.
• Employees: While not directly impacting other employees, executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• The restricted stock units will vest in four equal annual installments, subject to continuous service.
• The stock options will vest 25% on January 2, 2027, and 1/48th monthly thereafter, subject to continuous service.

Key Dates

Keywords

Gossamer Bio, GOSS, Faheem Hasnain, CEO, President, Director, Stock Award, Stock Options, Restricted Stock Units, Executive Compensation, Insider Transaction, Form 4